Cardiac metastasis from renal cell carcinoma, especially without neoplastic thrombosis of the vena cava, is extremely rare. The prognosis of patients with metastatic renal cell carcinoma has been radically influenced by the introduction of tyrosine kinase inhibitors, but very few reports in the literature have described their activity in heart metastasis. We report the case of a woman with a left ventricle metastasis from kidney cancer without renal vein involvement, who was treated with pazopanib. The patient achieved a prolonged partial response, with clear signs of metastasis devascularization and a favorable toxicity profile.

Schinzari, G., Monterisi, S., Signorelli, D., Cona, M. S., Cassano, A., Danza, F., Barone, C. A., Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity., <<TUMORI>>, 2014; (100): 298-300. [doi:10.1700/1778.19304] [http://hdl.handle.net/10807/72457]

Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.

Schinzari, Giovanni;Monterisi, Santa;Signorelli, Diego;Cona, Maria Silvia;Cassano, Alessandra;Danza, Francesco;Barone, Carlo Antonio
2014

Abstract

Cardiac metastasis from renal cell carcinoma, especially without neoplastic thrombosis of the vena cava, is extremely rare. The prognosis of patients with metastatic renal cell carcinoma has been radically influenced by the introduction of tyrosine kinase inhibitors, but very few reports in the literature have described their activity in heart metastasis. We report the case of a woman with a left ventricle metastasis from kidney cancer without renal vein involvement, who was treated with pazopanib. The patient achieved a prolonged partial response, with clear signs of metastasis devascularization and a favorable toxicity profile.
Inglese
Schinzari, G., Monterisi, S., Signorelli, D., Cona, M. S., Cassano, A., Danza, F., Barone, C. A., Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity., <<TUMORI>>, 2014; (100): 298-300. [doi:10.1700/1778.19304] [http://hdl.handle.net/10807/72457]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/72457
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact